A subsequent phase 2 randomized, placebo-controlled, double-blind trial (“UP Study”; ClinicalTrials.gov ID: NCT03840005;225)] enrolled thirty PD patients not carrying PRKN mutations. This evidence concerns the gene PRKN and Parkinson disease.